Online citations, reference lists, and bibliographies.
← Back to Search

Efficacy Of Inhaled Human Insulin In Type 1 Diabetes Mellitus: A Randomised Proof-of-concept Study

J. Skyler, W. Cefalu, I. Kourides, W. Landschulz, for The Inhaled Insulin Phase II Study Group
Published 2001 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Effective glycaemic control in type 1 diabetes mellitus usually requires two or more insulin injections daily. Inhaled intrapulmonary delivery of insulin offers a potential new way to deliver meal-related insulin, eliminating the need for preprandial injections. METHODS 73 patients with type 1 diabetes mellitus were studied in an open-label, proof-of-concept, parallel-group randomised trial. Patients in the experimental group received preprandial inhaled insulin plus a bedtime subcutaneous ultralente insulin injection. Patients in the control group received their usual insulin regimen of two to three injections per day. Participants monitored their blood glucose four times daily, and adjusted insulin doses weekly to achieve preprandial glucose targets of 5.6-8.9 mmol/L. The primary outcome measure was change in glycosylated haemoglobin (HbA1c) after 12 weeks. Secondary outcomes were fasting and postprandial glucose response to a mixed meal; hypoglycaemia frequency and severity; pulmonary function; and patients' satisfaction. FINDINGS Changes in HbA1c were indistinguishable between groups (difference 0.2% [95% CI -0.2 to 0.5]). Changes in fasting and postprandial glucose concentrations, and occurrence and severity of hypoglycaemia were also similar between groups. Inhaled insulin was well tolerated and had no effect on pulmonary function (ie, spirometry, lung volumes, diffusion capacity, and oxygen saturation). INTERPRETATION This proof-of-concept study shows that preprandial insulin can be given by inhalation in individuals with insulin-deficient type 1 diabetes as a less invasive alternative to conventional preprandial insulin injections.
This paper references
10.1056/NEJM199309303291401
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.
P. Saenger (1993)
10.2337/DIACARE.21.11.1910
Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
L. Heinemann (1998)
10.1056/NEJM198504253121702
Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes.
R. Salzman (1985)
10.2337/diacare.5.2.77
Absorption Kinetics and Biologic Effects of Subcutaneously Injected Insulin Preparations
M. Berger (1982)
10.2337/diacare.6.4.374
Importance of Timing of Preprandial Subcutaneous Insulin Administration in the Management of Diabetes Mellitus
G. Dimitriadis (1983)
10.1016/0169-409X(92)90002-8
(D) Routes of delivery: Case studies
J. Patton (1992)
10.2337/diab.43.3.396
[Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin
D. C. Howey (1994)
10.1136/bmj.280.6214.604
Timing of pre-breakfast insulin injection and postprandial metabolic control in diabetic children
A. Kinmonth (1980)
10.1056/NEJM199307293290502
The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.
P. Reichard (1993)
10.1111/j.1440-1754.1987.tb00275.x
Parenteral absorption of insulin from the lung in diabetic children
R. Elliott (1987)
10.2337/diacare.13.12.1265
Intensive Insulin Therapy for Treatment of Type I Diabetes
I. Hirsch (1990)
10.2337/diab.20.8.552
Insulin Across Respiratory Mucosae by Aerosol Delivery
F. W. Wigley (1971)
10.1016/S0169-409X(97)90003-X
Adv. Drug Delivery Rev.
F. Welt (1997)
10.1111/j.1464-5491.1994.tb00324.x
The Quest for Normoglycaemia: A Historical Perspective
R. Tattersall (1994)
10.1001/JAMA.1993.03500160076035
Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients.
B. Laube (1993)
10.2337/DIACARE.22.1.99
Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
H. Shamoon (1999)
10.1016/S0025-6196(12)62429-X
Intensive Insulin Therapy
J. Godine (1984)
10.7326/0003-4819-134-3-200102060-00011
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus
W. Cefalu (2001)
10.2337/diab.32.11.1040
Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol: Effectiveness and Reproducibility in Normal and Diabetic Subjects
A. Moses (1983)



This paper is referenced by
10.1517/14656566.4.7.1141
Insulin analogues and other developments in insulin therapy for diabetes
V. McAulay (2003)
10.1310/hpj4106-560
Insulin Human (rDNA Origin) Inhalation Powder
Dennis J. Cada (2006)
10.1586/14737167.8.1.33
Can inhaled insulin be used for the treatment of diabetes mellitus?
B. D. de Galan (2008)
10.1007/s11095-009-0034-9
Cell-Based Multiscale Computational Modeling of Small Molecule Absorption and Retention in the Lungs
Jing-yu Yu (2009)
Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus.
B. D. de Galan (2006)
10.1016/S0378-6080(03)80049-1
Insulin, glucagon, and hypoglycemic drugs
H. Krans (2003)
10.1517/17425247.4.1.63
First approved inhaled insulin therapy for diabetes mellitus
R. Jani (2007)
Pheroid℗ technology as a tool to change the administration route of selected pharmaceuticals from intravenous to oral
J. Kleynhans (2018)
10.1016/B978-0-12-409547-2.12415-1
Basic Principles of Formulation for Biotherapeutics: Approaches to Alternative Drug Delivery
L. Otvos (2017)
10.1046/J.1365-201X.2002.01006.X
Absorption of biologically active peptide hormones from the small intestine of rat.
S. Wheeler (2002)
10.1089/089426802760292609
Inhalation delivery of anticancer agents via HFA-based metered dose inhaler using methotrexate as a model drug.
M. S. Shaik (2002)
10.1146/ANNUREV.BIOENG.4.100101.132311
Bioengineering of therapeutic aerosols.
D. A. Edwards (2002)
10.1089/dia.2009.0059
Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine.
J. Rosenstock (2009)
10.7326/0003-4819-145-9-200611070-00009
Meta-Analysis: Efficacy and Safety of Inhaled Insulin Therapy in Adults with Diabetes Mellitus
L. Ceglia (2006)
10.7326/0003-4819-146-11-200706050-00013
Colorectal Screening after Polypectomy
F. Antaki (2007)
Achieving Patient Empowerment through active participation, increased knowledge and organisation
S. Werkö (2008)
10.1001/ARCHINTE.163.11.1306
Clinical significance, pathogenesis, and management of postprandial hyperglycemia.
J. Gerich (2003)
10.1201/B14327-2
Management of type 2 diabetes
R. Leslie (2002)
10.1016/S1262-3636(06)72804-X
Alternatives routes of insulin delivery.
V. Lassmann-Vague (2006)
10.1089/DIA.2007.0217
Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease.
S. Mudaliar (2007)
10.1016/j.jconrel.2008.01.019
Efficacy of pulmonary insulin delivery in diabetic rats: use of a model-based approach in the evaluation of insulin powder formulations.
M. Amidi (2008)
10.1157/13101797
Eficacia y seguridad de la insulina inhalada en el tratamiento de la diabetes mellitus
A. Méndez (2007)
10.1016/J.ARCMED.2005.03.012
Insulin therapy: current alternatives.
F. Gómez-Pérez (2005)
10.1089/152091504773731302
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
C. Kapitza (2004)
In vitro and in vivo behavior of insulin delivery systems based on poly(ethylene glycol)-grafted poly(methacrylic acid) hydrogels
Nikhil Jayant Kavimandan (2005)
10.3132/dvdr.2006.027
Inhaled insulin (Exubera®): combining efficacy and convenience
S. Bellary (2006)
10.15157/EA.V0I0.10129
1. tüüpi diabeedi uued ravimeetodid
Kaire Heilman (2007)
10.1016/S1526-0542(03)00032-0
Role of inhaler competence and contrivance in "difficult asthma".
M. Everard (2003)
10.1080/08035250410024934
Insulin treatment in children and adolescents
R. Williams (2004)
Glucose-responsive Implantable Polymeric Microdevices for “Smart” Insulin Therapy of Diabetes
M. Chu (2014)
10.1038/nrd2399
Protein therapeutics: a summary and pharmacological classification
B. Leader (2008)
10.1016/S0140-6736(00)05051-0
Inhaled insulin in type 1 diabetes
M. Cavallo (2001)
See more
Semantic Scholar Logo Some data provided by SemanticScholar